Abiopharma

WESTLAKE CORP (WLK) Reports the reporting period Financial Results WESTLAKE CORP (WLK) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: 1632
• Net Income: 12
• EPS: Not disclosed
• Cash and equivalents: 2288
  • 7 billion, a net loss of $169 million, or $
  • 31 per share, and EBITDA (earnings before interest expense, income taxes, depreciation and amortization) of $150 million. Earnings in the first quarter were impacted by the previously announced $67 million settlement of certain litigation involving direct purchasers of PVC pipe and fittings in the United States and $18 million of charges related to previously announced facility shutdowns, including epoxy, North American chlorovinyls and styrene, and cost saving actions for a combined $85 million impact (the "Identified Items"). Excluding the effects of the Identified Items, the net loss in the first quarter of 2026 was $100 million, or $
  • 77 per share, and EBITDA was $235 million.Compared to the fourth quarter of 2025, Westlake's first quarter of 2026 sales volume increased 6% (excluding sales attributable to plant closures and acquisitions) while average sales price increased 1%. Housing and Infrastructure Products sales increased 10%, driven by 10% sales volume growth (excluding the ACI acquisition) that more than offset a 5% decline in average sales price. Performance and Essential Materials sales increased 2% over the same period of time due to a 3% increase in average sales price and a 3% increase in sales volume (excluding plant shutdowns) that was partially offset by a 5% sales impact from plant shutdowns.EXECUTIVE COMMENTARY"The first quarter of 2026 began to reflect our cost reduction initiatives announced in